



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/039,898
	Filing Date	January 3, 2002
	First Named Inventor	David Lauffer
	Group Art Unit	1646
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/98-19 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
VB	B1		WO 97/16446	Merck Sharp & Dohme Limited	09-May-1997		
VB	B2		WO 97/16190	Guilford Pharmaceuticals, Inc.	09-May-1997		
VB	B3		WO 96/41609	Vertex Pharmaceuticals Incorporated	27-Dec-1996		
VB	B4		0 289 227 A1	Syntex Pharma Ltd.	02-Nov-1988		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
VB	C1	Hori, M., et al., "N-(1,2-Diphenylethyl)piperazines," retrieved from STN Database accession no. 85:33075.
VB	C2	Choi, S.W., et al., "Design, Synthesis, and Biological Evaluation of Novel Non-Piperazine Analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-phenylpropyl)piperazines as Dopamine Transporter Inhibitors," <i>J. Med. Chem.</i> , 42(18):3647-3656 (1999).
VB	C3	Tsizin, Y.S., et al., "The structure and anthelmintic activity of tricyclic analogs of praziquantel and 4-acyl-2-piperazinones," retrieved from STN Database accession no. 117:39808.

V. Balasubramanian

6/13/03

 RECEIVED
 OCT 22 2002
 TECH CENTER 1600/2900